Details of the Drug Combinations

General Information of This Drug (ID: DMX6OE3)

• Drug Name: Dabrafenib (DMX6OE3)
• Synonyms: 1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436

Indication

Melanoma; ICD 11: 2C30; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
APR-246 + Dabrafenib	DC5N5GF	APR-246	Melanoma	[2]
Trametinib + Dabrafenib	DCEV54D	Trametinib	Cancer	[3]
Trametinib + Dabrafenib	DCGYK2H	Trametinib	Glioma	[4]
Trametinib + Dabrafenib	DCI71OM	Trametinib	Non-small-cell lung cancer	[5]
Trametinib + Dabrafenib	DCRRRIO	Trametinib	Melanoma	[6]
Vemurafenib + Dabrafenib	DCM00AS	Vemurafenib	Metastatic Melanoma (Carrying BRAF V600 Mutation)	[7]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Trametinib + Dabrafenib	DCXQC9Q	Trametinib	Melanoma	[8]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] ClinicalTrials.gov (NCT03391050) A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
• [3] ClinicalTrials.gov (NCT01336634) Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT03754179) Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
• [7] ClinicalTrials.gov (NCT02052193) Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
• [8] Clinical pipeline report, company report or official report of novartis.